Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Is a non-smoker or moderate smoker (≤ 20 cigarettes/day or the equivalent) who agrees to consume no more than 10 cigarettes or equivalent/day from the time of screening and throughout the period of sample collection.
Has a body mass index (BMI) ≥ 18.5 and ≤ 40.0 kg/m\^2,
Is judged to be in good health based on medical history, physical examination, vital signs, and laboratory safety tests. Has no clinically significant electrocardiogram (ECG) abnormality, as deemed by the Investigator.
Females are non-pregnant, and non-breast feeding. If female with reproductive potential, they must demonstrate they are not pregnant and agree to use (and/or have their partner use) two (2) acceptable methods of birth control beginning at screening, throughout the study and until 2 weeks after dosing of study drug.
Participants with ESRD requiring HD has been maintained on stable regimen of thrice-weekly HD for at least 3 months prior to first dosing.
Healthy participants, must be within ± 10 years of the mean age of participants with RI; and must be within ± 10 kg of the mean weight of participants with RI.
You may not be if
Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit, or expected during the conduct of the study.
Has a history or presence of clinically significant medical or psychiatric condition or disease.
Has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk by participating in the study.
Has a history or presence of alcoholism or drug abuse within the past 6 months prior to dosing.
Has a history or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds (including sulfonamides).
Has a history or presence of renal artery stenosis; or major risk factors for renal/urinary calculi.
Has rapidly fluctuating renal function as determined by historical measurements.
Female who is pregnant, or lactating.
Has positive results for urine or saliva drug and/or urine or breath alcohol at screening or check-in.
Is positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
Has positive macroscopic hematuria or crystalluria at screening or check-in.
Is unable to refrain from or anticipates using any medication or substance including prescription or over-the-counter, vitamin supplements, natural or herbal supplements.
Has been on a diet incompatible with the on-study diet, within the 28 days prior to dosing.
Has donated blood or had significant blood loss within 56 days prior to dosing.
Has donated plasma within 7 days prior to dosing.
Has taken gefapixant at any time prior to dosing on the current study.
Has participated in another clinical trial within 28 days prior to dosing based on the latest blood collection or dosing.
